Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00073125 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

A Phase 2 study of Carcinoma, Renal Cell, sponsored by Abbott.

Completed
Registry status
Phase 2
Development phase
103
Enrollment target
18
Study locations

NCT00073125: Completed Phase 2 study of Carcinoma, Renal Cell, sponsored by Abbott.

NCT00073125 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by Abbott. The registered enrollment target is 103 participants, below the 280-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (63% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00073125, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 2
Development phase
103 participants
Enrollment target
18
Study locations

Study Summary

The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG ABT-510/Thrombospondin-1 mimetic

Study Locations (18)

Texas

  • US Oncology, P.A. - Dallas
  • Texas Cancer Center - Fort Worth
  • Texas Cancer Center - Fort Worth
  • MD Anderson Cancer Center - Houston
  • Baylor College of Medicine - Houston

Arizona

  • Virginia G. Piper Cancer Center - Scottsdale
  • Arizona Cancer Center - Tucson

California

  • UCLA School of Medicine - Los Angeles
  • Clinical Trials and Research Associates - Montebello

Florida

  • The Center for Hematology-Oncology - Boca Raton

Illinois

  • University of Chicago Medical Center - Chicago

Indiana

  • Central indiana Cancer Center - Indianapolis

Kansas

  • Kansas City Cancer Centers Southwest - Overland Park

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2003-05
Phase Phase 2
Abbott

181 total trials

What the finished NCT00073125 record still lists

NCT00073125 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which ABT-510/Thrombospondin-1 mimetic is the first listed.

NCT00073125 lists 18 locations in 12 states (Texas, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT00073125 about?

NCT00073125 is a clinical study titled "Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma". The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.

What is the current status of trial NCT00073125?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2003-05.

What conditions does trial NCT00073125 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT00073125?

The interventions under investigation include: ABT-510/Thrombospondin-1 mimetic (DRUG).

Who is sponsoring clinical trial NCT00073125?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00073125 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00073125's enrollment target sits among peer trials

103 16th of 34 higher than 19 of 34 other Carcinoma, Renal Cell trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00073125, the US trial registry maintained by the National Library of Medicine. NCT00073125 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.